Mallinckrodt Revenue and Competitors

Location

$97M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Mallinckrodt's estimated annual revenue is currently $1.1B per year.(i)
  • Mallinckrodt's estimated revenue per employee is $321,600
  • Mallinckrodt's total funding is $97M.

Employee Data

  • Mallinckrodt has 3434 Employees.(i)
  • Mallinckrodt grew their employee count by 0% last year.

Mallinckrodt's People

NameTitleEmail/Phone
1
VPReveal Email/Phone
2
President, Mallinckrodt Enterprises LLC & VP and Corporate Controller, Mallinckrodt plcReveal Email/Phone
3
Security Officer IIIReveal Email/Phone
4
VP Market AccessReveal Email/Phone
5
EVP and Head Corporate DevelopmentReveal Email/Phone
6
VP ManufacturingReveal Email/Phone
7
VP, Head Global MarketingReveal Email/Phone
8
ControllerReveal Email/Phone
9
VP, Global ProcurementReveal Email/Phone
10
VP Medical DevicesReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$48.8M2435%N/AN/A
Add Company

What Is Mallinckrodt?

Tyco Healthcare/Mallinckrodt, based in St. Louis, Missouri, manufactures and markets medical products. Our mission is to improve healthcare for patients worldwide by providing superior products that sustain breathing, diagnose disease and relieve pain. We are committed to producing products that bring better healthcare to patients, more value to medical professionals, greater opportunity to employees, and increased earnings to reward Tyco shareholders.

keywords:N/A

$97M

Total Funding

3434

Number of Employees

$1.1B

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mallinckrodt News

2022-04-20 - Postoperative Pain Therapeutics Market Growth and Demands ... Digital Journal

Postoperative Pain Therapeutics Market Growth and Demands ... Digital Journal

2022-04-13 - Mallinckrodt Announces Publication of Real-World Data from ... PR Newswire

Mallinckrodt Announces Publication of Real-World Data from ... PR Newswire

2022-03-22 - Silence Therapeutics and Mallinckrodt Announce Submission of ... BioSpace

Silence Therapeutics and Mallinckrodt Announce Submission of ... BioSpace